More Articles

Building trust in biosimilars main challenge of EGA Conferences | Posted 01/09/2009

So far, three types of biosimilar medicines have been approved in the EU – somatropin (human growth hormone, hGH), epoetin (erythropoietin, EPO) and filgrastim (granulocyte colony-stimulating facto...

DIA EuroMeeting: EU needs automatic pricing to get generics to market Conferences | Posted 01/09/2009

“The EU needs greater regulatory capacity and automatic pricing and reimbursement to deal with the number of generics required to serve the market”, said Mr Georg Stark, Joint Managing Director of...

Teva looking for ‘major’ acquisition Generics/News | Posted 31/08/2009

Just a year after swallowing the US$7.4 billion (Euros 5.3 billion) Barr Laboratories buy, Teva Pharmaceutical Industries is ready for another ‘major’ acquisition and may look beyond generic drugs...

WHO has prequalification multisource (generic) guideline Policies & Legislation | Posted 31/08/2009

On 18 June 2009, WHO published a Prequalification Update, informing that a guideline on submission of documentation for prequalification of multisource (generic) has been completed and that Finishe...

US bill proposes Comparative-Effectiveness Research Centre Policies & Legislation | Posted 31/08/2009

Mr Randall Stafford of the Stanford Prevention Research Center and Mr Caleb Alexander of the University of Chicago, USA have published several challenges that must be met if comparative-effectivene...

BIO wants to delay biodissimilars as long as possible Biosimilars/News | Posted 31/08/2009

Biotech drugs are big revenue earners. Their sales growth rate may have slipped back into single figures last year, but according to IMS Health data they still accounted for more than 37% of the gr...

Obama wants to introduce US biosimilars pathway Biosimilars/News | Posted 31/08/2009

US President Barack Obama plans to fund part of his healthcare reform plans by backing an approval pathway for generic biologicals. As reported by Christopher Spillane in Scrip News, Mr Obama lobbi...

Watson to acquire Arrow to double generics business Generics/News | Posted 31/08/2009

Watson Pharmaceuticals announced it has entered into a definitive agreement to acquire privately held Arrow Group for US$1.75 billion (Euros 1.25 billion) in cash and stock. The combination of Wats...